Creatine Monohydrate
Creatine monohydrate is the most-studied performance supplement: strength SMD 0.235-0.317 across Lanhers 2015, lean mass +0.68 kg per Delpino 2022, and ISSN-position-stand safety across 685 RCTs with no serious adverse events (Antonio 2021). 5 g/day at the standard dose, no loading required.
Creatine Monohydrate scored 7.3 / 10 (💪 Strong recommend) on the BioHarmony scale as a Substance → Vitamin / Mineral / Nutrient.
What It Is
Creatine monohydrate is the most-studied performance and cognitive supplement available, with 685+ randomized controlled trials and over 12,800 participants documenting safety and efficacy across more than 50 years of research. The molecule occurs naturally in human muscle and brain tissue and concentrates in red meat, fish, and animal proteins; supplementation matches or exceeds the dietary intake achievable from omnivore diets and reaches saturation in vegetarian and vegan baseline-deficient populations within weeks.
The mechanism is rapid adenosine triphosphate regeneration via the phosphocreatine system, supporting high-intensity work bursts in skeletal muscle and sustained cognitive performance under demand. Secondary effects include GLUT4 upregulation, satellite cell activation contributing to muscle hypertrophy, methyl donor sparing in the SAM cycle, and brain phosphocreatine buffering that protects cognitive performance under sleep deprivation and acute stress per Watanabe et al. 2002.
Standard maintenance is 3 to 5 grams per day with no need for loading. Optional 20 g/day loading saturates stores in a week instead of four; both protocols reach the same end state. The Kreider 2017 ISSN position stand supports daily intake at this range as safe across decades of use. Standard maintenance saturates muscle in approximately 28 days. Most users report no dramatic subjective effect; benefits show up on the bar, the scale, in cognitive testing under demand, and on long-term muscle and bone preservation in older adults.
Terminology
- Phosphocreatine (PCr): the high-energy phosphate form of creatine stored in muscle and brain; donates a phosphate to ADP to regenerate ATP during high-intensity work
- SMD: standardized mean difference, a meta-analysis effect size measure; SMD 0.2 = small, 0.5 = moderate, 0.8 = large per Cohen's convention
- WMD: weighted mean difference, raw effect size in original units (e.g. kilograms of lean mass)
- ISSN: International Society of Sports Nutrition; publishes position stands on supplement efficacy and safety
- Creapure: the patented German monohydrate manufactured by AlzChem with FDA GRAS Notice GRN-931; community purity benchmark
- GAA: guanidinoacetic acid, a creatine precursor with emerging brain-bioavailability evidence; contraindicated in GAMT-deficient individuals
- NSF Certified for Sport: third-party purity certification for tested athletes; verifies absence of WADA-banned contaminants
- NINDS NET-PD LS-1: the National Institutes of Neurological Disorders and Stroke long-term Parkinson's trial that tested 10 g/day creatine for 5 years and was stopped for futility
- GAMT deficiency: rare genetic disorder of creatine biosynthesis; affected individuals must avoid GAA-containing products
- Cystatin C: alternative renal-function marker preferred over creatinine for GFR assessment in creatine users (avoids the metabolic-artifact confound)
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 3 routes and 4 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Oral powder | Micronized monohydrate (Creapure preferred; NSF Certified for Sport for tested athletes) | 3-5 g/day maintenance; optional loading 20 g/day split × 5-7 days | 5-10 g/day daily; community 5 g/day plain consensus; cognitive enhancement 10-20 g/day |
| Oral capsule | Monohydrate capsules (typically 750-1000 mg per cap) | 3-5 g/day (4-7 capsules) | Same |
| Oral combination | Monohydrate + hydrochloride + guanidinoacetic acid (GAA) blend | Limited RCT evidence; doses parallel monohydrate | 5-7 g/day combined; LVLUP Crevolution is the canonical product |
Protocols
Standard maintenance Clinical
- Dose
- 5 g/day oral
- Frequency
- Daily, anytime (slight post-workout edge)
- Duration
- Indefinite
ISSN-recommended baseline. Saturates muscle in 28 days. Most users settle here permanently.
Optional loading Clinical
- Dose
- 20 g/day split × 5-7 days, then 5 g/day
- Frequency
- 4 × 5 g daily during loading
- Duration
- 5-7 days load, then indefinite maintenance
Saturates muscle in a week. GI upset risk at single doses above 10 g; split dosing mitigates. Adoption ~30% and declining.
Cognitive / sleep-deprivation Mixed
- Dose
- 10-20 g/day oral
- Frequency
- Daily, split AM + PM
- Duration
- 4-12 weeks for cognitive endpoints
Used in [Watanabe 2002](https://pubmed.ncbi.nlm.nih.gov/11985880/) and TBI / sleep-deprivation research. Higher GI risk; split into two doses. Not required for general-purpose cognition.
Brain-bioavailability blend Anecdotal
- Dose
- 5-7 g/day combined monohydrate + HCl + GAA
- Frequency
- Daily
- Duration
- Indefinite
LVLUP Crevolution. Early research only; not equivalent to monohydrate evidence base. NEVER use in confirmed or suspected GAMT deficiency.
Use-Case Specific Dosing
| Use Case | Dose | Notes |
|---|---|---|
| Cognition Focus | 5 g per day standard; researchers have used 10 to 20 g per day for cognitive endpoints | Stronger effects in vegetarians, females, sleep-deprived, and ages 18 to 60. |
| Depression | 6 g per day | Toniolo RCT in bipolar depression; 66.7% vs 18.2% remission. |
| Geriatric | 3 to 5 g per day with resistance training | Muscle, bone, and cognitive benefits in older adults. |
| Strength Power | 5 g per day; optional loading | SMD 0.43 overall. Loading provides faster saturation but not greater long-term effect. |
How this score is calculated →
Upside contribution: 4.03
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 4.5 | 1.125 | |
| Breadth of Benefits | 15% | 4.5 | 0.675 | |
| Evidence Quality | 25% | 4.2 | 1.050 | |
| Speed of Onset | 10% | 3.5 | 0.350 | |
| Durability | 10% | 3.0 | 0.300 | |
| Bioindividuality Upside | 15% | 3.5 | 0.525 | |
| Total | 4.025 |
Upside Rationale
Creatine Monohydrate has real upside when strength and power, muscle growth, and cognition and focus are the target, but the benefit case should stay tied to measured outcomes. Avgerinos 2018 supports the lead signal: 6 RCTs; short-term memory and processing speed; vegetarian and elderly amplification. Lanhers 2015 broadens the case, and Delpino 2022 helps ground the mechanism, dosing, or safety context. The best use of Creatine Monohydrate is narrow: pick one goal, define the marker, then judge whether the intervention moves that marker within a reasonable window. Creatine Monohydrate gets weaker when mechanisms are stretched beyond the studied population or one endpoint is used to justify every possible use case.
Efficacy (4.5/5.0). Creatine produces measurable, replicable benefits across strength, lean mass, cognitive performance, and bone density when combined with appropriate training. Strength effects are small-to-moderate per Lanhers et al. 2015: lower-limb global SMD 0.235, upper-limb SMD 0.317, chest press SMD 0.677. Lean mass gains average +0.68 kg overall and +1.46 kg in male-only subgroups per Delpino 2022. Older adults gain +1.37 kg lean mass with concurrent resistance training per Chilibeck 2017. Cognitive benefits emerge under sleep deprivation and in vegetarian populations per Avgerinos 2018 and Dolan 2019. The defining negative finding is the NINDS NET-PD LS-1 Parkinson's trial stopped for futility, which rules out neurodegenerative monotherapy.
Breadth of benefits (4.5/5.0). Few supplements span as many systems with consistent evidence: skeletal muscle strength and hypertrophy, brain phosphocreatine buffering and cognition, bone density in older adults, methylation sparing, mitochondrial energy support, and emerging signals in glycemic control and bipolar depression augmentation per Toniolo 2017. Mechanism (ATP regeneration buffer) is conserved across tissues, which underpins the breadth.
Evidence quality (4.2/5.0). 685+ RCTs with 12,800+ participants, multiple Cochrane positions, and the Kreider 2017 ISSN position stand establish the evidence base. The 0.3-point integrity adjustment reflects industry funding concentration: AlzChem and Creapure underwrite a substantial fraction of published evidence, including the Kreider lab and JISSN journal. Independent kidney safety meta-analyses (de Souza 2019) and the Antonio 2021 misconception review provide independent counterweight. The the fabricated Kondo cognition-meta citation and Yoon-Bipolar-Disorders attribution citations sometimes cited in older creatine reviews are fabrications and should not be used.
Speed of onset (3.5/5.0). Strength effects within 1-4 weeks; lean mass gains measurable at 8-12 weeks; muscle saturation at 28 days without loading or 5-7 days with optional 20 g/day load. Cognitive benefits under sleep deprivation can appear acutely. Subjective energy lift is mild; the buffer effect emerges under demand rather than as baseline alertness. Most users see results before they feel them.
Durability (3.0/5.0). Effects fade over 4-6 weeks of cessation as muscle stores return to baseline. The intervention is functionally a maintenance dependency: the gains persist as long as supplementation continues, then revert. Long-term users report sustained training capacity and lean mass benefits across years of consistent dosing without escape from the underlying maintenance requirement.
Bioindividuality (3.5/5.0). 60-70% responder rate is well-documented; baseline muscle creatine stores predict response. Vegetarians and vegans show amplified response from low baseline; omnivore populations near-saturated from dietary intake show smaller relative gains. Genetic variants in SLC6A8 (creatine transporter) explain some non-response. Despite the response variance, the intervention works for the majority and the cost makes a 4-12 week trial low-stakes.
Downside contribution: 1.76 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 1.5 | 0.450 | |
| Side Effect Profile | 15% | 1.5 | 0.225 | |
| Financial Cost | 5% | 1.0 | 0.050 | |
| Time/Effort Burden | 5% | 1.0 | 0.050 | |
| Opportunity Cost | 5% | 1.0 | 0.050 | |
| Dependency / Withdrawal | 15% | 1.5 | 0.225 | |
| Reversibility | 25% | 1.0 | 0.250 | |
| Total | 1.300 | |||
| Harm subtotal × 1.4 | 1.610 | |||
| Opportunity subtotal × 1.0 | 0.150 | |||
| Combined downside | 1.760 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 0.420 |
Downside Rationale
Creatine Monohydrate is not mainly limited by a single obvious danger; the bigger downside is uncertainty, medical fit, sourcing, and opportunity cost. Kreider 2017 is the main caution anchor: Foundational 87-citation position stand; safe up to 30 g/day for 5 years. Risk changes by route, dose, baseline condition, medication stack, and whether a clinician is checking the right labs or symptoms. That matters more for peptides, hormones, injectables, and clinic procedures than for low-burden food-like supplements. Creatine Monohydrate makes the most sense when product quality is verifiable, contraindications are screened, and the user can stop quickly if the tradeoff becomes worse than the target problem. The clean read is to treat Creatine Monohydrate as conditional, then let response data decide whether it earns a longer place in the stack.
Safety risk (1.5/5.0). Worst-case safety risk is essentially zero across the trial corpus. The Antonio 2021 safety review across 685 trials and 12,800+ participants found no serious adverse events attributable to creatine. Side-effect incidence in creatine groups (4.60%) is statistically indistinguishable from placebo (4.21%, p=0.828). The persistent kidney damage and DHT/hair loss myths are debunked: serum creatinine elevation is a benign metabolic byproduct (use cystatin C for GFR assessment); the Van der Merwe 2009 DHT finding has not replicated in 15+ years and was contradicted by a recent prospective RCT. Narrow contraindications: pre-existing CKD stage 3+ (eGFR below 60), GAMT deficiency (for GAA-containing products only), and McArdle disease.
Side effect profile (1.5/5.0). GI upset is the only common side effect, dose-dependent and dramatically reduced by split dosing. Single 10 g boluses produce diarrhea in approximately 55% of users versus 29% with split dosing. Cosmetic intracellular water retention adds 1-2 kg in the first weeks, often misread as fat gain; this is reversible on cessation. No cardiovascular, hepatic, neurological, or endocrine adverse signals across the full evidence base.
Financial cost (1.0/5.0). Among the cheapest evidence-backed supplements available: Creapure-based bulk monohydrate runs $0.10-0.15 per 5 g serving, or roughly $3-5 per month at standard maintenance. Capsule formats and brand-name premiums increase cost 2-4×. Generic monohydrate from quality manufacturers (Bulk Supplements, Nutricost, Klean Athlete, Thorne) provides the cheapest path. Cost is essentially trivial relative to outcomes.
Time / effort burden (1.0/5.0). One scoop or capsule daily, mixed in any liquid or taken with any meal. No timing complexity, no preparation, no meal-pairing requirement (slight post-workout edge for trained athletes is real but marginal). Saturates without loading in 28 days; loading optional. Effort is essentially zero relative to outcomes.
Opportunity cost (1.0/5.0). Does not crowd out other interventions. Stacks with protein, beta-alanine, citrulline, and most other sports supplements without conflict. The only documented interaction is the contested caffeine-blunting effect from Vandenberghe 1996, not replicated consistently since. Effectively zero displacement of other interventions.
Dependency / withdrawal (1.5/5.0). Functional dependency at the saturation level: muscle stores deplete over 4-6 weeks of cessation, returning to dietary-baseline. No addiction signal, no withdrawal syndrome, no rebound. Stopping produces gradual reversion of training-capacity and lean-mass benefits but no acute physiological effect.
Reversibility (1.0/5.0). Fully reversible. Stopping returns muscle and brain creatine stores to dietary baseline within 4-6 weeks. No surgical procedures, no permanent biochemical changes, no enduring effects on tissue function or genetic expression beyond the sustained-use period. Sits at the most-reversible end of the supplementation spectrum.
Verdict
Creatine Monohydrate is a 7.3/10 fit for people weighing strength and power, muscle growth, and cognition and focus, especially when the goal is a tracked experiment with clear endpoints. The strongest evidence anchor is Avgerinos 2018: 6 RCTs; short-term memory and processing speed; vegetarian and elderly amplification. Lanhers 2015 adds a second signal, but Creatine Monohydrate still has gaps around large trials, long-term outcomes, responder profiles, or real-world adherence. That makes Creatine Monohydrate useful for a defined reader, while weaker for broad anti-aging or catch-all wellness claims. In practice, Creatine Monohydrate belongs after basics, diagnosis when relevant, and a stop rule based on symptoms, labs, sleep, or performance.
✅ Best for: Strength and muscle-growth athletes (the core indication, 50+ years of evidence). Adults over 50 for muscle preservation, bone density, and cognitive support, especially when combined with resistance training. Vegetarians and vegans who run lower baseline muscle and brain creatine stores and respond more strongly to supplementation. Cognitive workers under sleep deprivation, demanding mental load, or acute stress conditions where the brain phosphocreatine buffer matters. Anyone seeking the highest evidence-to-cost ratio supplement available across nearly any health goal.
❌ Avoid if: You have pre-existing chronic kidney disease (eGFR below 60, CKD stage 3 or higher) without nephrologist supervision. You have McArdle disease (myophosphorylase deficiency) or GAMT deficiency (for GAA-containing creatine blends only). You are using a HCl-only or ethyl-ester creatine product (no efficacy benefit, 5-15× the cost). You expect dramatic subjective enhancement: most users feel nothing, and benefits emerge as performance and body composition data, not subjective experience. You have a history of disordered eating where the temporary intracellular water weight (1-2 kg in first weeks) would trigger compensatory restriction.
Use Case Breakdown
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Strength / Power: 8.6/10
Score: 8.6/10Creatine Monohydrate earns 8.6/10 for strength and power because Lanhers 2015 reports Lower-limb global SMD 0.235 (small-to-moderate). Chilibeck 2017 points in the same direction, but route, dose, baseline status, and outcome tracking decide whether Creatine Monohydrate matters for this use case. The practical move is to define one strength and power marker before starting, then judge Creatine Monohydrate by that marker instead of by mechanism alone. Creatine Monohydrate is most defensible when the target is specific and the user is willing to stop if the signal is absent.
Muscle Growth / Hypertrophy: 8.0/10
Score: 8.0/10For muscle growth, Creatine Monohydrate scores 8.0/10 because Chilibeck 2017 reports Older adults; +1.37 kg lean mass; leg press SMD 0.24. Delpino 2022 points in the same direction, but route, dose, baseline status, and outcome tracking decide whether Creatine Monohydrate matters for this use case. The practical move is to define one muscle growth marker before starting, then judge Creatine Monohydrate by that marker instead of by mechanism alone. Creatine Monohydrate is most defensible when the target is specific and the user is willing to stop if the signal is absent.
Cognition / Focus: 6.6/10
Score: 6.6/10Evidence for Creatine Monohydrate in cognition and focus lands at 6.6/10 because Dolan 2019 reports Brain creatine and cognitive processing review. Avgerinos 2018 points in the same direction, but route, dose, baseline status, and outcome tracking decide whether Creatine Monohydrate matters for this use case. The practical move is to define one cognition and focus marker before starting, then judge Creatine Monohydrate by that marker instead of by mechanism alone. Creatine Monohydrate is most defensible when the target is specific and the user is willing to stop if the signal is absent.
Geriatric / Aging Population: 7.6/10
Score: 7.6/10The geriatric case for Creatine Monohydrate is 7.6/10 because Chilibeck 2017 reports Older adults; +1.37 kg lean mass; leg press SMD 0.24. Van 2009 points in the same direction, but route, dose, baseline status, and outcome tracking decide whether Creatine Monohydrate matters for this use case. The practical move is to define one geriatric marker before starting, then judge Creatine Monohydrate by that marker instead of by mechanism alone. Creatine Monohydrate is most defensible when the target is specific and the user is willing to stop if the signal is absent.
Recovery / Repair: 7.0/10
Score: 7.0/10Mechanistically, Creatine Monohydrate fits recovery and repair at 7.0/10 because Vandenberghe 1996 reports Original caffeine-blunting finding; not consistently replicated since. Dolan 2019 points in the same direction, but route, dose, baseline status, and outcome tracking decide whether Creatine Monohydrate matters for this use case. The practical move is to define one recovery and repair marker before starting, then judge Creatine Monohydrate by that marker instead of by mechanism alone. Creatine Monohydrate is most defensible when the target is specific and the user is willing to stop if the signal is absent.
Memory: 7.0/10
Score: 7.0/10The strongest memory argument for Creatine Monohydrate is 7.0/10 because Avgerinos 2018 reports 6 RCTs; short-term memory and processing speed; vegetarian and elderly amplification. Dolan 2019 points in the same direction, but route, dose, baseline status, and outcome tracking decide whether Creatine Monohydrate matters for this use case. The practical move is to define one memory marker before starting, then judge Creatine Monohydrate by that marker instead of by mechanism alone. Creatine Monohydrate is most defensible when the target is specific and the user is willing to stop if the signal is absent.
Energy / Fatigue: 7.0/10
Score: 7.0/10Creatine Monohydrate is a 7.0/10 energy fit because Watanabe 2002 reports Cognitive performance under mental load and sleep deprivation. The score stays conditional because Creatine Monohydrate still needs better outcome data for this exact use case. The practical move is to define one energy marker before starting, then judge Creatine Monohydrate by that marker instead of by mechanism alone. Creatine Monohydrate is most defensible when the target is specific and the user is willing to stop if the signal is absent.
Body Composition / Fat Loss: 6.0/10
Score: 6.0/10For body composition, Creatine Monohydrate scores 6.0/10 because Delpino 2022 reports WMD +0.68 kg lean overall (+1.46 kg males-only). Chilibeck 2017 points in the same direction, but route, dose, baseline status, and outcome tracking decide whether Creatine Monohydrate matters for this use case. The practical move is to define one body composition marker before starting, then judge Creatine Monohydrate by that marker instead of by mechanism alone. Creatine Monohydrate is most defensible when the target is specific and the user is willing to stop if the signal is absent.
Healthspan: 6.0/10
Score: 6.0/10The healthspan case for Creatine Monohydrate is 6.0/10 because Kreider 2017 reports Foundational 87-citation position stand; safe up to 30 g/day for 5 years. Lanhers 2015 points in the same direction, but route, dose, baseline status, and outcome tracking decide whether Creatine Monohydrate matters for this use case. The practical move is to define one healthspan marker before starting, then judge Creatine Monohydrate by that marker instead of by mechanism alone. Creatine Monohydrate is most defensible when the target is specific and the user is willing to stop if the signal is absent.
Bone / Joint Health: 5.6/10
Score: 5.6/10The practical bone and joint support read on Creatine Monohydrate is 5.6/10 because Kreider 2017 reports Foundational 87-citation position stand; safe up to 30 g/day for 5 years. Lanhers 2015 points in the same direction, but route, dose, baseline status, and outcome tracking decide whether Creatine Monohydrate matters for this use case. The practical move is to define one bone and joint support marker before starting, then judge Creatine Monohydrate by that marker instead of by mechanism alone. Creatine Monohydrate is most defensible when the target is specific and the user is willing to stop if the signal is absent.
Mood / Emotional Regulation: 5.6/10
Score: 5.6/10For users targeting mood, Creatine Monohydrate earns 5.6/10 because Toniolo 2017 reports Augmentation; 67% vs 18% remission at 6 g/day. The score stays conditional because Creatine Monohydrate still needs better outcome data for this exact use case. The practical move is to define one mood marker before starting, then judge Creatine Monohydrate by that marker instead of by mechanism alone. Creatine Monohydrate is most defensible when the target is specific and the user is willing to stop if the signal is absent.
Methylation Support: 5.6/10
Score: 5.6/10Creatine Monohydrate looks most relevant to methylation at 5.6/10 because Kreider 2017 reports Foundational 87-citation position stand; safe up to 30 g/day for 5 years. Lanhers 2015 points in the same direction, but route, dose, baseline status, and outcome tracking decide whether Creatine Monohydrate matters for this use case. The practical move is to define one methylation marker before starting, then judge Creatine Monohydrate by that marker instead of by mechanism alone. Creatine Monohydrate is most defensible when the target is specific and the user is willing to stop if the signal is absent.
Injury Recovery: 5.6/10
Score: 5.6/10The strongest injury recovery argument for Creatine Monohydrate is 5.6/10 because Dolan 2019 reports Brain creatine and cognitive processing review. The score stays conditional because Creatine Monohydrate still needs better outcome data for this exact use case. The practical move is to define one injury recovery marker before starting, then judge Creatine Monohydrate by that marker instead of by mechanism alone. Creatine Monohydrate is most defensible when the target is specific and the user is willing to stop if the signal is absent.
Mitochondrial: 5.0/10
Score: 5.0/10Creatine Monohydrate earns 5.0/10 for mitochondrial because Kreider 2017 reports Foundational 87-citation position stand; safe up to 30 g/day for 5 years. Lanhers 2015 points in the same direction, but route, dose, baseline status, and outcome tracking decide whether Creatine Monohydrate matters for this use case. The practical move is to define one mitochondrial marker before starting, then judge Creatine Monohydrate by that marker instead of by mechanism alone. Creatine Monohydrate is most defensible when the target is specific and the user is willing to stop if the signal is absent.
Neuroprotection: 5.0/10
Score: 5.0/10Mechanistically, Creatine Monohydrate fits neuroprotection at 5.0/10 because Watanabe 2002 reports Cognitive performance under mental load and sleep deprivation. Dolan 2019 points in the same direction, but route, dose, baseline status, and outcome tracking decide whether Creatine Monohydrate matters for this use case. The practical move is to define one neuroprotection marker before starting, then judge Creatine Monohydrate by that marker instead of by mechanism alone. Creatine Monohydrate is most defensible when the target is specific and the user is willing to stop if the signal is absent.
Frequently Asked Questions
How much creatine should I take per day?
Standard maintenance is 3-5 g/day taken at any time, with no loading required for most users. The Kreider 2017 ISSN position stand supports this baseline across 500+ RCTs. Optional loading at 20 g/day split into four doses for 5-7 days saturates muscle stores faster but produces the same end state. Cognitive and sleep-deprivation research uses 5-10 g/day and sometimes up to 20 g/day. The Watanabe 2002 sleep-deprivation work used higher doses but split throughout the day. Heavier individuals do not need proportionally more; saturation is muscle-mass-dependent within a fairly narrow band.
Does creatine cause hair loss?
No. The persistent concern traces to Van der Merwe et al. 2009, a single 3-week study in 20 college rugby players that showed elevated DHT in the creatine group, but with the creatine group's baseline DHT 23% lower than placebo and all values remaining within normal clinical limits throughout. No replication exists across 15+ years. A 2025 12-week prospective RCT directly tested DHT and hair outcomes and found zero difference between creatine and placebo. The popular media framing is a textbook hasty generalization from a methodologically compromised pilot.
Is creatine bad for your kidneys?
Not in healthy kidneys. The de Souza et al. 2019 systematic review and the recent BMC Nephrology meta-analysis (21 studies) both confirm no renal impairment in healthy adults. The widely cited 'kidney damage' concern reflects a measurement artifact: creatine supplementation elevates serum creatinine through normal metabolic conversion, not nephrotoxicity. Use cystatin C for GFR assessment in creatine users to avoid this artifact. Pre-existing chronic kidney disease (CKD stage 3 or higher, eGFR below 60) warrants nephrologist supervision before initiating, primarily due to nitrogen-load considerations.
Should vegetarians and vegans take more creatine?
Same dose, often stronger response. Vegetarians and vegans typically run 30-50% lower baseline muscle creatine stores because dietary creatine is concentrated in red meat, fish (especially herring), and other animal proteins. Standard 3-5 g/day at maintenance produces a larger relative jump in saturation, with more pronounced strength, lean mass, and cognitive benefits compared to omnivore users who are already near-saturated from diet. Brain creatine response is also amplified per the Avgerinos 2018 cognitive meta-analysis subgroup analysis.
Creatine monohydrate vs HCl vs ethyl ester: which is best?
Monohydrate wins decisively on cost and evidence. The Kreider 2017 ISSN position stand reviews the evidence and concludes that no alternative form has demonstrated superior efficacy in head-to-head trials. Hydrochloride (HCl) is sold at 5-15× the price of monohydrate without RCT evidence of superiority; community phrase: marketing-inflated. Ethyl ester is degraded to creatinine in the stomach and is essentially inactive. Buffered Kre-Alkalyn shows no advantage over monohydrate. The monohydrate plus hydrochloride plus guanidinoacetic acid (GAA) blend (Crevolution) is an emerging niche with early brain-bioavailability evidence but is contraindicated in GAMT-deficient individuals.
Does creatine improve cognitive function?
Yes, with conditions. The Avgerinos et al. 2018 meta-analysis of 6 RCTs found short-term memory and processing speed benefits, with stronger effects in vegetarian and elderly populations. Watanabe 2002 and Dolan 2019 support the sleep-deprivation cognitive maintenance evidence. The widely cited (but later-fabricated) Kondo cognition meta-analysis is a citation fabrication and should not be used. Healthy, well-rested, omnivore adults show modest baseline cognitive effects; sleep-deprived, stressed, vegetarian, or aging populations show the strongest signal.
How quickly does creatine start working?
Strength benefits emerge within 1-4 weeks of consistent dosing. Lean mass gains become measurable at 8-12 weeks per Delpino 2022. Optional 20 g/day loading saturates muscle stores within a week; standard 5 g/day reaches the same saturation in about 28 days. Cognitive benefits in sleep-deprived users can appear acutely. Stopping creatine returns muscle stores to baseline over 4-6 weeks; functional benefits fade on the same timeline. Most users report no dramatic subjective effect at any point: the gains show up on the bar, the scale, or in objective testing rather than as a felt experience.
What about the NINDS Parkinson's trial that failed?
The NINDS NET-PD LS-1 trial tested 10 g/day creatine in 1,741 early Parkinson's patients for 5 years and was stopped for futility per Kieburtz et al. 2015 JAMA. This is the most consequential negative finding in the creatine literature and definitively rules out creatine monotherapy as a Parkinson's-progression intervention. Animal TBI and ALS models continue to show benefit; the NINDS result should temper any neurodegenerative-disease claims and frame creatine's neuroprotective mechanism as supportive rather than therapeutic in established disease.
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | Dimensions changed | New score |
|---|---|---|
| Independent (non-Creapure-funded) large RCT replicates Devries and Phillips 2014 minimal lean mass gains | Efficacy 4.5 to 4.0; Evidence 4.2 to 3.8 | 7.0 / 10 💪 Strong recommend |
| GAA + monohydrate + HCl combination (Crevolution) demonstrates clinically meaningful brain bioavailability advantage in independent RCT | Efficacy 4.5 to 4.7; Bioindiv 3.5 to 3.8 | 8.0 / 10 ✅ Top-tier |
| New independent meta-analysis confirms cognitive benefits in healthy rested adults (not just sleep-deprived or vegetarian) | Breadth 4.5 to 4.8; Evidence 4.2 to 4.5 | 8.1 / 10 ✅ Top-tier |
| Long-term (10+ year) safety study identifies any organ-system signal | Safety 1.5 to 2.5 | 7.2 / 10 💪 Strong recommend |
| Full-spectrum aging cohort study confirms healthspan signal independent of training | Breadth 4.5 to 4.8; Bioindiv 3.5 to 4.0 | 8.1 / 10 ✅ Top-tier |
Key Evidence Sources
- Kreider RB et al. 2017 - International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation, JISSN. Foundational 87-citation position stand; safe up to 30 g/day for 5 years
- Lanhers C et al. 2015 - Creatine supplementation and lower limb strength performance: meta-analysis, Sports Medicine. Lower-limb global SMD 0.235 (small-to-moderate)
- Chilibeck PD et al. 2017 - Effect of creatine supplementation during resistance training on lean tissue mass and muscular strength in older adults, Open Access J Sports Med. Older adults; +1.37 kg lean mass; leg press SMD 0.24
- Delpino FM et al. 2022 - Influence of creatine supplementation on body composition and physical performance: meta-analysis, Nutrition. WMD +0.68 kg lean overall (+1.46 kg males-only)
- Antonio J et al. 2021 - Common questions and misconceptions about creatine supplementation, JISSN. Safety review; 500+ studies; comprehensive misconception debunking
- de Souza E Silva A et al. 2019 - Creatine supplementation does not affect kidney function: meta-analysis, JSMS. GFR unaffected in healthy adults; cystatin C recommended for monitoring
- Van der Merwe J et al. 2009 - Three weeks of creatine monohydrate supplementation affects DHT/T ratio in college-aged rugby players, Clin J Sport Med. Single n=20 3-week study, no replication in 15+ years; 2025 RCT contradicts
- Vandenberghe K et al. 1996 - Caffeine counteracts the ergogenic action of muscle creatine loading, JAP. Original caffeine-blunting finding; not consistently replicated since
- Avgerinos KI et al. 2018 - Effects of creatine supplementation on cognitive function in healthy individuals: meta-analysis, Exp Gerontol. 6 RCTs; short-term memory and processing speed; vegetarian and elderly amplification
- Watanabe A, Kato N, Kato T 2002 - Effects of creatine on mental fatigue and cerebral hemoglobin oxygenation, Neurosci Res. Cognitive performance under mental load and sleep deprivation
- Dolan E et al. 2019 - Beyond muscle: the effects of creatine supplementation on brain creatine, cognitive processing, and traumatic brain injury, Eur J Sport Sci. Brain creatine and cognitive processing review
- Kieburtz K et al. 2015 - Effect of creatine monohydrate on clinical progression in patients with Parkinson disease (NINDS NET-PD LS-1), JAMA. n=1,741; 5 years; 10 g/day; stopped for futility; defining negative neuroprotection finding
- Toniolo RA et al. 2017 - A randomized, double-blind, placebo-controlled, proof-of-concept trial of creatine monohydrate as adjunctive treatment for bipolar depression, J Neural Transm. Augmentation; 67% vs 18% remission at 6 g/day
Holistic Evidence Profile
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: High
Citations: Kreider 2017, Lanhers 2015, Chilibeck 2017, Delpino 2022, Antonio 2021, Kieburtz 2015, Avgerinos 2018
Pre-RCT-Era Pharmacology and Use
Confidence: Medium
Citations: Chevreul 1832, Lieberman 1881, Chanutin 1926
Traditional Medicine Systems
Confidence: Limited
Holistic Evidence for Creatine Monohydrate
All three lenses converge on creatine as a baseline metabolic substrate rather than a pharmacological intervention. Traditional omnivore diets reach near-saturation through red meat and fish; vegetarians and modern indoor athletes need supplementation to match. Modern RCT evidence quantifies what dietary patterns demonstrate empirically: creatine improves muscular and cognitive performance under demand, with the strongest relative response in baseline-deficient populations. The intervention is essentially nutrient-restoration for the modern lifestyle, not enhancement above natural human function.
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- Creatinine Baseline (pre-protocol)
- eGFR During | Expected Stable
- ALT During | Expected Stable
- AST During | Expected Stable
- Creatine Kinase During | Expected Watch
Pulse Dimensions to Watch
- Energy During | Expected Up | Primary
- Body During | Expected Up | Primary
- Drive During | Expected Up | Secondary
Subjective Signals (Daily Voice Card)
- Training Output Scale 1-5 | During | Expected Up
- Cognitive Stamina Scale 1-5 | During | Expected Up
- Water Retention Scale 1-5 | During | Expected Watch
Red Flags: Stop and Consult
- Severe muscle cramping with dark urine
- Rapid unexplained weight gain with swelling
Other interventions for Strength / Power
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–3.6, Caution 3.7–4.7, Neutral 4.8–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–7.9, Top-tier 8.0+.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 3.025 − 0.420 = 2.605
Formula v0.5 maps EV = 0 to score 5.0. Above neutral, 1 EV point equals 1 score point. Below neutral, 1 EV point equals about 0.71 score points, so EV = −7 reaches 0.0 while EV = +5 reaches 10.0. Both sides use the full 5-point half-scale.
Score = 5 + (2.605 / 5) × 5 = 7.6 / 10
